esophageal-squamous-cell-carcinoma

Documents about esophageal-squamous-cell-carcinoma

• The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy#852188ClinicalTrials.gov
• Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC#1033626ClinicalTrials.gov
• Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery#805596ClinicalTrials.gov
• A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors#806826ClinicalTrials.gov
• Expression and clinical significance of LTA4H in esophageal squamous cell carcinoma#343161Figshare
• Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors#448280ClinicalTrials.gov
• A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China#906979ClinicalTrials.gov
• Establishment and Histopathological Characterization of a KYSE-30 Subcutaneous Xenograft Model of Esophageal Squamous Cell Carcinoma#351835ODU Digital Commons
• Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer#858279ClinicalTrials.gov
• Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade#902010ClinicalTrials.gov
• Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC#980709ClinicalTrials.gov
• GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma#870624ClinicalTrials.gov
• Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy#387139ClinicalTrials.gov
• Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma#834794ClinicalTrials.gov
• A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC#481772ClinicalTrials.gov
• Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal Carcinoma#891898ClinicalTrials.gov
• Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy#993275ClinicalTrials.gov
• Plastic Stents Compared With Metal Stents in Treating Patients With Malignant Dysphagia Caused by Esophageal Cancer or Gastroesophageal Junction Cancer#863150ClinicalTrials.gov
• PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer#834143ClinicalTrials.gov
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors#804465ClinicalTrials.gov
• A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC#824772ClinicalTrials.gov
• Whether it is More Appropriate to Spray Lugol's Solution From Cervical Esophagus to Esophagogastric Junction#969437ClinicalTrials.gov
• Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC#979950ClinicalTrials.gov
• Early Tumor Shrinkage and Clinical Outcomes for Esophageal Squamous Cell Carcinoma Patients Treated with Immune Checkpoint Inhibitors: Real-World Observational Study#439915Springer Nature OA
• Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors#824951ClinicalTrials.gov
• Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer#869418ClinicalTrials.gov
• Study of ADCT-301 in Patients With Selected Advanced Solid Tumors#814039ClinicalTrials.gov
• Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination#979820ClinicalTrials.gov
• Non-structural maintenance of chromosome condensin I complex subunit H knockdown suppresses malignant progression of esophageal squamous cell carcinoma via the Wnt/β-catenin signaling pathway.#666091NCBI PubMed Central
• Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors#833985ClinicalTrials.gov
• Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer#896867ClinicalTrials.gov
• Preoperative Fibrinogen-to-Prealbumin Ratio and in-Hospital Postoperative Pneumonia After Minimally Invasive McKeown Esophagectomy for Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study with Infection Phenotype Profiling.#480840NCBI PubMed Central
• Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy#966136ClinicalTrials.gov
• Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors#899717ClinicalTrials.gov
• Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2#148778ClinicalTrials.gov
• Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study#162479ClinicalTrials.gov
• Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin#828894ClinicalTrials.gov
• Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction#810374ClinicalTrials.gov
• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies#830569ClinicalTrials.gov
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors#849329ClinicalTrials.gov
• PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY#865339ClinicalTrials.gov
• Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial#993647ClinicalTrials.gov
• Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors#829094ClinicalTrials.gov
• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)#844803ClinicalTrials.gov
• An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging#851159ClinicalTrials.gov
• Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer#825854ClinicalTrials.gov
• Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery#888611ClinicalTrials.gov
• Node-Sparing Short-Course Radiotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A Prospective Single-Arm, Phase II Study#914047ClinicalTrials.gov
• FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.#836487ClinicalTrials.gov
• FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)#882957ClinicalTrials.gov